Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2023-02-14 12:50 pm Unchanged | 13G | ONCOSEC MED INC PAR $0.000 ONCS | Avidity Partners Management LP | 0 0% | 0 (Unchanged) | View |
2023-02-14 12:41 pm Sale | 13G | ADICET BIO INC ACET | Avidity Partners Management LP | 0 0% | -3,034,004 (Position Closed) | View |
2023-02-14 12:19 pm Sale | 13G | VIRIDIAN THERAPEUTICS INC VRDN | Avidity Partners Management LP | 0 0% | -1,278,261 (Position Closed) | View |
2023-02-14 12:02 pm Purchase | 13G | ZENTALIS PHARMACEUTICALS INC C ZNTL | Avidity Partners Management LP | 5,150,000 9% | 2,127,210 (+70.37%) | View |
2023-02-02 3:15 pm Purchase | 13G | PRAXIS PRECISION MEDICINES INC PRAX | Avidity Partners Management LP | 4,100,000 8.7% | 4,100,000 (New Position) | View |
2022-12-08 10:22 am Purchase | 13G | KARYOPHARM THERAPEUTICS INC KPTI | Avidity Partners Management LP | 11,351,819 9.9% | 11,351,819 (New Position) | View |
2022-10-27 09:56 am Purchase | 13G | ESSA PHARMA INC EPIX | Avidity Partners Management LP | 3,750,000 8.5% | 3,750,000 (New Position) | View |
2022-09-20 4:35 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Avidity Partners Management LP | 2,120,000 9.9% | 2,120,000 (New Position) | View |
2022-09-16 10:16 am Purchase | 13G | AKERO THERAPEUTICS INC AKRO | Avidity Partners Management LP | 3,105,000 6.9% | 3,105,000 (New Position) | View |
2022-06-16 4:38 pm Purchase | 13G | ARVINAS INC ARVN | Avidity Partners Management LP | 3,239,838 6.1% | 3,239,838 (New Position) | View |
2022-02-14 09:18 am Purchase | 13G | IDEAYA BIOSCIENCES INC IDYA | Avidity Partners Management LP | 2,553,000 6.6% | 82,821 (+3.35%) | View |
2022-02-11 8:54 pm Purchase | 13G | SYNDAX PHARMACEUTICALS INC SNDX | Avidity Partners Management LP | 5,244,019 9.9% | 494,019 (+10.40%) | View |
2022-02-11 8:39 pm Purchase | 13G | SCYNEXIS INC SCYX | Avidity Partners Management LP | 2,239,278 9.3% | 259,478 (+13.11%) | View |
2022-02-11 8:34 pm Purchase | 13G | ONCOSEC MED INC PAR $0.000 ONCS | Avidity Partners Management LP | 2,945,000 7.5% | 993,000 (+50.87%) | View |
2022-02-11 8:18 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Avidity Partners Management LP | 2,205,687 7.3% | 735,297 (+50.01%) | View |
2022-02-11 8:10 pm Purchase | 13G | VIRIDIAN THERAPEUTICS INC VRDN | Avidity Partners Management LP | 1,278,261 5.9% | 157,336 (+14.04%) | View |
2022-02-11 7:52 pm Purchase | 13G | PHASEBIO PHARMACEUTICALS INC C PHAS | Avidity Partners Management LP | 4,405,000 9.2% | 120,000 (+2.80%) | View |
2022-02-11 7:43 pm Sale | 13G | IVERIC BIO INC ISEE | Avidity Partners Management LP | 6,955,000 6.1% | -270,000 (-3.74%) | View |
2022-02-11 7:18 pm Purchase | 13G | GRITSTONE BIO INC GRTS | Avidity Partners Management LP | 6,990,194 9.9% | 2,443,380 (+53.74%) | View |
2022-02-11 7:12 pm Sale | 13G | CARDIFF ONCOLOGY INC CRDF | Avidity Partners Management LP | 0 0% | -2,153,600 (Position Closed) | View |